Insider · CIK 0001844824
Jacquelyn L Sumer
Files at CGEM (Cullinan Therapeutics, Inc.). First filing Dec 20, 2024, latest Feb 25, 2026.
Jacquelyn L Sumer files SEC Form 4 as officer at CGEM (Cullinan Therapeutics, Inc.). Since Dec 20, 2024, Jacquelyn L Sumer has reported 0 open-market buys worth $0 and 5 open-market sells worth $208k, the latest filed on Feb 25, 2026.
A track record needs three past buys with six months of prices behind them; Jacquelyn L Sumer has 0, so none is measured yet.
The newest scored trade: sold $52k of CGEM on Feb 24, 2026, filed Feb 25, 2026, scored 37 (weak). In the last 12 months: 0 buys worth $0 and 3 sells worth $137k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CGEM: Cullinan Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Cullinan Therapeutics, Inc. | $52k 3,601 shares | -3% | +148% from low0% from high | |
| 37Weak | Cullinan Therapeutics, Inc. | $51k 3,742 shares | -3% | +137% from low-2% from high | |
| 36Weak | Cullinan Therapeutics, Inc. | $34k 3,480 shares | -3% | +74% from low-23% from high | |
| 35Weak | Cullinan Therapeutics, Inc. | $32k 3,756 shares | -3% | 0% from low-53% from high | |
| 36Weak | Cullinan Therapeutics, Inc. | $40k 3,482 shares | -4% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +2,470 | $8.60 | $21k | 130,559 | Jul 2, 2026 |
| Feb 24, 2026 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -3,601 | $14.47 | $52k | 128,089 | Feb 25, 2026 |
| Feb 20, 2026 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -3,742 | $13.62 | $51k | 131,690 | Feb 23, 2026 |
| Feb 18, 2026 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +230,000 | $0.00 | $0 | 230,000 | Feb 19, 2026 |
| Dec 18, 2025 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -3,480 | $9.67 | $34k | 135,432 | Dec 19, 2025 |
| Feb 25, 2025 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -3,756 | $8.53 | $32k | 136,895 | Feb 27, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 140,651 | Feb 21, 2025 |
| Feb 19, 2025 | CGEM Cullinan Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 21, 2025 |
| Dec 18, 2024 | CGEM Cullinan Therapeutics, Inc. | SOpen-market sale Common Stock | -3,482 | $11.41 | $40k | 90,651 | Dec 20, 2024 |
Questions about Jacquelyn L Sumer
Answered from the filings on this page, as of the latest one.
Is Jacquelyn L Sumer buying or selling?
In the last 12 months Jacquelyn L Sumer reported 0 open-market buys worth $0 and 3 open-market sells worth $137k on SEC Form 4; the latest was sold $52k of CGEM on Feb 24, 2026. Grants, option exercises and tax withholding are not counted.
How did Jacquelyn L Sumer's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jacquelyn L Sumer has 0.
Where does Jacquelyn L Sumer file Form 4?
Jacquelyn L Sumer has filed Form 4 at CGEM (Cullinan Therapeutics, Inc.) as Chief Legal Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.